In accordance with the Article 228 of Royal Legislative Decree 4/2015, dated 23 October, which enacts the consolidated text of the Securities Market Act, LABORATORIO REIG JOFRE SA ("Reig Jofre" or "the Company") informs about the publication schedule for 2019 quarterly results.
• 2018 year-end: Thursday, February 28, 2019
• First quarter 2019: Thursday, May 9, 2018
• Second quarter 2019: Thursday, July 25, 2018
• Third quarter 2019: Thursday, November 14, 2018
• 2019 year-end: Friday, February 28, 2020
Results will be released before the market opening.
Any change on this calendar will be reported in due course.
Yours faithfully,
Adolf Rousaud
Secretary of the Board of Directors
Attachments
Original document
Permalink
Disclaimer
Laboratorio Reig Jofre SA published this content on 23 January 2019 and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on 23 January 2019 20:43:02 UTC
Laboratorio Reig Jofre SA, formerly Natraceutical SA, is a Spain-based company primarily engaged in the research, development, manufacturing and marketing of drugs. The Companyâs activities are divided into four business divisions: Industrial Services, providing production services for third parties; Pharma, selling own pharmaceuticals under a range of brands, such as Reig Jofre, Medea, Orravan, Bioglan and Sala; Reaserch and Development (R&D) and Regulatory, including the development of indications for existing molecules, as well as generics and molecular diagnostics, among others; and Biotech, offering biopharmaceutical support services, such as analytical and process development, quality control and assurance, as well as stability studies. The Company also provides nutritional cosmetics, and food supplements, among others. It operates worldwide in Europe, Africa, the Americas, Australia and Asia through a number of subsidiaries, including Chiesi Espana SA and Oryzon Genomics SA.
LABORATORIO REIG JOFRE, S.A. 
